Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-219C in Relapsed/Refractory Autoimmune Hemolytic Anemia
NCT07530380Phase 1Recruiting
- Sponsor
- The Second Affiliated Hospital of Anhui Medical University
- Start
- Apr 2026
- Primary completion
- Dec 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QT-219C in autoimmune hemolytic anemia (AIHA), sponsored by The Second Affiliated Hospital of Anhui Medical University. Primary endpoints: Incidence of Dose-Limiting Toxicities, Incidence of Adverse Events up to 12 Months and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
QT-219C
03
Conditions
autoimmune hemolytic anemia (AIHA)
Beyond the preview
Go deeper on NCT07530380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530380.